Antiepileptic drug pharmacokinetics and interactions: Impact on treatment of epilepsy

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

An understanding of epilepsy therapy's pharmacokinetic and drug interaction principles-combined with knowledge of antiepileptic drug (AED) clinical pharmacology-allows more effective use of these drugs. The most desirable pharmacokinetic characteristic is a linear relationship between dose and steady-state concentration, as this determines the ease or difficulty in determining the appropriate dose. Drug-drug interactions affecting AED metabolism are common, clinically important, and, until recently, often unpredictable. Advances in molecular biology have identified specific enzymes responsible for AED metabolism and interactions. Clinicians now can identify potential interactions and avoid or manage them by adjusting drug dosage. Most newer AEDs follow or approximate linear pharmacokinetics, are absorbed extensively and consistently, are not significantly bound to plasma proteins, do not form active metabolites, and have few, if any, drug interactions. In cases where interactions occur between newer AEDs and other drugs, knowledge of these interactions reduces the likelihood of serious adverse events. The pharmacokinetics of the newer AEDs simplify drug dosing and monitoring and should lead to improved patient care.

Original languageEnglish (US)
Pages (from-to)139S-151S
JournalPharmacotherapy
Volume20
Issue number8 II
StatePublished - Aug 24 2000

Fingerprint

Drug Interactions
Anticonvulsants
Epilepsy
Pharmacokinetics
Pharmaceutical Preparations
Therapeutics
Clinical Pharmacology
Drug Monitoring
Blood Proteins
Molecular Biology
Patient Care
Enzymes

Cite this

Antiepileptic drug pharmacokinetics and interactions : Impact on treatment of epilepsy. / Cloyd, J. C.; Remmel, R. P.

In: Pharmacotherapy, Vol. 20, No. 8 II, 24.08.2000, p. 139S-151S.

Research output: Contribution to journalArticle

@article{0ad4dadac1fe4c3faa869ea9ef4f0188,
title = "Antiepileptic drug pharmacokinetics and interactions: Impact on treatment of epilepsy",
abstract = "An understanding of epilepsy therapy's pharmacokinetic and drug interaction principles-combined with knowledge of antiepileptic drug (AED) clinical pharmacology-allows more effective use of these drugs. The most desirable pharmacokinetic characteristic is a linear relationship between dose and steady-state concentration, as this determines the ease or difficulty in determining the appropriate dose. Drug-drug interactions affecting AED metabolism are common, clinically important, and, until recently, often unpredictable. Advances in molecular biology have identified specific enzymes responsible for AED metabolism and interactions. Clinicians now can identify potential interactions and avoid or manage them by adjusting drug dosage. Most newer AEDs follow or approximate linear pharmacokinetics, are absorbed extensively and consistently, are not significantly bound to plasma proteins, do not form active metabolites, and have few, if any, drug interactions. In cases where interactions occur between newer AEDs and other drugs, knowledge of these interactions reduces the likelihood of serious adverse events. The pharmacokinetics of the newer AEDs simplify drug dosing and monitoring and should lead to improved patient care.",
author = "Cloyd, {J. C.} and Remmel, {R. P.}",
year = "2000",
month = "8",
day = "24",
language = "English (US)",
volume = "20",
pages = "139S--151S",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "8 II",

}

TY - JOUR

T1 - Antiepileptic drug pharmacokinetics and interactions

T2 - Impact on treatment of epilepsy

AU - Cloyd, J. C.

AU - Remmel, R. P.

PY - 2000/8/24

Y1 - 2000/8/24

N2 - An understanding of epilepsy therapy's pharmacokinetic and drug interaction principles-combined with knowledge of antiepileptic drug (AED) clinical pharmacology-allows more effective use of these drugs. The most desirable pharmacokinetic characteristic is a linear relationship between dose and steady-state concentration, as this determines the ease or difficulty in determining the appropriate dose. Drug-drug interactions affecting AED metabolism are common, clinically important, and, until recently, often unpredictable. Advances in molecular biology have identified specific enzymes responsible for AED metabolism and interactions. Clinicians now can identify potential interactions and avoid or manage them by adjusting drug dosage. Most newer AEDs follow or approximate linear pharmacokinetics, are absorbed extensively and consistently, are not significantly bound to plasma proteins, do not form active metabolites, and have few, if any, drug interactions. In cases where interactions occur between newer AEDs and other drugs, knowledge of these interactions reduces the likelihood of serious adverse events. The pharmacokinetics of the newer AEDs simplify drug dosing and monitoring and should lead to improved patient care.

AB - An understanding of epilepsy therapy's pharmacokinetic and drug interaction principles-combined with knowledge of antiepileptic drug (AED) clinical pharmacology-allows more effective use of these drugs. The most desirable pharmacokinetic characteristic is a linear relationship between dose and steady-state concentration, as this determines the ease or difficulty in determining the appropriate dose. Drug-drug interactions affecting AED metabolism are common, clinically important, and, until recently, often unpredictable. Advances in molecular biology have identified specific enzymes responsible for AED metabolism and interactions. Clinicians now can identify potential interactions and avoid or manage them by adjusting drug dosage. Most newer AEDs follow or approximate linear pharmacokinetics, are absorbed extensively and consistently, are not significantly bound to plasma proteins, do not form active metabolites, and have few, if any, drug interactions. In cases where interactions occur between newer AEDs and other drugs, knowledge of these interactions reduces the likelihood of serious adverse events. The pharmacokinetics of the newer AEDs simplify drug dosing and monitoring and should lead to improved patient care.

UR - http://www.scopus.com/inward/record.url?scp=0033854906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033854906&partnerID=8YFLogxK

M3 - Article

C2 - 10937813

AN - SCOPUS:0033854906

VL - 20

SP - 139S-151S

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 8 II

ER -